Results 131 to 140 of about 86,262 (260)
From haemostasis to immunity: The expanding frontiers of platelet biology
Platelets are versatile cells whose functions extend far beyond haemostasis and thrombosis, actively regulating innate and adaptive immunity, angiogenesis, lymphangiogenesis, liver regeneration, atherosclerosis and tumour metastasis. This demonstrates their central role in various physiological processes and multiple life‐threatening diseases ...
Xun Grace Wu, Nicole Tomei, Heyu Ni
wiley +1 more source
Drug-Induced Immune Thrombocytopenia Secondary to Trimethoprim-Sulfamethoxazole. [PDF]
Cimperman C +6 more
europepmc +1 more source
A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia. [PDF]
Rojas K, Ahmed A, Khan SJ, Singh GH.
europepmc +1 more source
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon +14 more
wiley +1 more source
Paediatric‐onset autoimmune cytopenia: How can we reduce the long‐term mortality?
British Journal of Haematology, EarlyView.
Nathalie Aladjidi +21 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Primary Sjögren's syndrome-associated immune thrombocytopenia: from pathogenesis to treatment. [PDF]
Liu C, Zheng Z, He T, Zhang G, Fu G.
europepmc +1 more source
Abstract Background and Purpose Rare but severe adverse events (AEs) associated with mRNA‐lipid nanoparticle (LNP) COVID‐19 vaccines, such as Comirnaty, include anaphylaxis and inflammatory organ disorders, but their underlying mechanisms are poorly understood. We aimed to develop an animal model to study these phenomena.
László Dézsi +13 more
wiley +1 more source
Successful eltrombopag discontinuation in paraneoplastic immune thrombocytopenia: a case report. [PDF]
Tarasconi E +6 more
europepmc +1 more source

